Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib and docetaxel in metastatic castration-resistant prostate cancer
ISRCTN22566729Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of saracatinib, docetaxel and prednisolone in prostate cancer (PCa) (3 arms), sponsored by NHS Greater Glasgow and Clyde. Started Sep 2011; status: completed.
02
Drugs
saracatinibdocetaxelprednisolone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ISRCTN22566729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN22566729.